Abstract
Background: The rate of recurrence after cytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastasis of colorectal origin remains high despite important advances in multimodal treatment. Previous studies have demonstrated that there is remaining disease in the normal-looking peritoneum after a complete CRS and HIPEC in up to 30% of the patients. Fluorescence-guided (FG) surgery is revolutionizing oncologic surgery as it can signal in real time primary or metastatic lesions thanks to indocyanine green (ICG) or targeted dyes as EMI-137, a specific dye for colorectal cancer cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
